Chang-Lu Hu

机构：Anhui Provincial Hospital

发表论文 109 篇 · 总被引 1157 次 · h-index 16

代表论文

• Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials (2023 · Journal of Clinical Oncology · 被引 180)
• Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2023 · The Lancet Oncology · 被引 109)
• Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE) (2024 · Journal of Thoracic Oncology · 被引 43)
• Black carbon derived from pyrolysis of maize straw and polystyrene microplastics affects soil biodiversity (2023 · The Science of The Total Environment · 被引 13)
• A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma (2024 · European Journal of Cancer · 被引 11)
• A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors (2025 · Journal of bone oncology · 被引 2)